Literature DB >> 10689549

Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women.

A B Erbağci1, N Yilmaz, I Kutlar.   

Abstract

Information on menstrual cycle dependent variation of tumor markers in healthy women is a subject of diagnostic efficiency and has an impact in elucidating the normal function of these markers. In this study midfollicular and midluteal concentrations of serum CEA, AFP, CA 19-9, CA 125, CA 15-3 and their relations with LH, FSH, prolactin, estradiol and progesterone were evaluated during ovulatory cycles in a group of 23 healthy female individuals. Samples were collected on the 7th and 21st day of the same menstrual cycle. Tumor marker and hormone concentrations were determined with chemiluminescence or electrochemiluminescence EIA methods. A significant phase-dependent difference was observed for CA 15-3, midluteal concentrations (mean +/- SEM; 26.33 +/- 1.56 U/ml) higher than the midfollicular (mean +/- SEM; 19.27 +/- 1.49 U/ml) concentrations (p < 0.001). But an obvious difference for other tumor markers investigated did not exist. Significant correlations of follicular and luteal CA 125 levels with body mass index of the subjects were observed (r:0.52, p < 0.05 and r:0.57, p < 0.005, respectively). CA 15-3 antigen is a product of the MUC-1 gene which is expressed in abundance by endometrial epithelial cells in the secretory phase of the menstrual cycle which may be the potential source of variability. The association of CA 125 levels with obesity suggests a possible role of adipose tissue in CA 125 metabolism. In conclusion our data suggest that in healthy women serum CA 15-3 levels are significantly elevated in the midluteal phase of the menstrual cycle compared to midfollicular phase. Therefore, consideration of menstrual cycle dependent variability for CA 15-3 appears indicated in interpretation of individual results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10689549      PMCID: PMC3850873          DOI: 10.1155/1999/960934

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  9 in total

Review 1.  Epidemiologic perspective on immune-surveillance in cancer.

Authors:  Daniel W Cramer; Olivera J Finn
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

2.  Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.

Authors:  Simone P Pinheiro; Susan E Hankinson; Shelley S Tworoger; Bernard A Rosner; John R McKolanis; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

3.  Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.

Authors:  Emanuela Anastasi; Teresa Granato; Giulia Giovanna Marchei; Valentina Viggiani; Barbara Colaprisca; Sara Comploj; Maria Gabriella Reale; Luigi Frati; Cecilia Midulla
Journal:  Tumour Biol       Date:  2010-05-20

4.  Impact of post-laparoscopic sleeve gastrectomy weight loss on C-reactive protein, lipid profile and CA-125 in morbidly obese women.

Authors:  Ghada Morshed; Samah M Fathy
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2015-12-15       Impact factor: 1.195

5.  Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Authors:  Noriaki Arakawa; Hiroshi Kobayashi; Naohiro Yonemoto; Yusuke Masuishi; Yoko Ino; Hiroshi Shigetomi; Naoto Furukawa; Norihisa Ohtake; Yohei Miyagi; Fumiki Hirahara; Hisashi Hirano; Etsuko Miyagi
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

6.  Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.

Authors:  Hsin-Yao Wang; Chia-Hsun Hsieh; Chiao-Ni Wen; Ying-Hao Wen; Chun-Hsien Chen; Jang-Jih Lu
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

7.  CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding.

Authors:  Kumar U Nithin; M G Sridhar; K Srilatha; S Habebullah
Journal:  Afr Health Sci       Date:  2018-12       Impact factor: 0.927

Review 8.  CA125 and Ovarian Cancer: A Comprehensive Review.

Authors:  Parsa Charkhchi; Cezary Cybulski; Jacek Gronwald; Fabian Oliver Wong; Steven A Narod; Mohammad R Akbari
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

9.  Effects of Hibiscus sabdariffa Calyxes Aqueous Extract on Antioxidant Status and Histopathology in Mammary Tumor-Induced in Rats.

Authors:  Thierry Renaud Bassong; Larissa Vanelle Kenmogne; Charline Florence Awounfack; Derek Tantoh Ndinteh; Dieudonné Njamen; Stéphane Zingue
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-13       Impact factor: 2.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.